Search Result

Results for "

histone

" in MCE Product Catalog:

By Targets:	HDAC (90) Histone Acetyltransferase (41) Histone Demethylase (52) Histone Methyltransferase (54) Adenosine Receptor (5) Akt (2) Aldehyde Dehydrogenase (ALDH) (1) Amyloid-β (2) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (63) Aurora Kinase (3) Autophagy (14) Bacterial (5) Bcl-2 Family (1) Biochemical Assay Reagents (1) Caspase (2) CDK (3) Cholinesterase (ChE) (4) CMV (2) DNA Alkylator/Crosslinker (1) DNA Methyltransferase (4) E1/E2/E3 Enzyme (1) Endogenous Metabolite (12) Epigenetic Reader Domain (17) Estrogen Receptor/ERR (1) Ferroptosis (3) Fluorescent Dye (1) Fungal (1) GCGR (1) Haspin Kinase (2) HIF/HIF Prolyl-Hydroxylase (1) HIV (1) HSP (3) HSV (2) Influenza Virus (4) Interleukin Related (4) Keap1-Nrf2 (4) MDM-2/p53 (5) MicroRNA (3) Microtubule/Tubulin (2) Mitochondrial Metabolism (2) Mitophagy (2) MMP (1) Monoamine Oxidase (2) NF-κB (1) Orthopoxvirus (3) Parasite (2) PDGFR (2) Phosphodiesterase (PDE) (5) PI3K (2) PKA (3) PKC (2) Polo-like Kinase (PLK) (3) PROTACs (4) Protein Arginine Deiminase (5) SARS-CoV (1) Sirtuin (1) STAT (1) Survivin (1) TNF Receptor (5) Topoisomerase (1) VD/VDR (1) VEGFR (2)
By Research Areas:	Cancer (245) Cardiovascular Disease (4) Endocrinology (2) Infection (17) Inflammation/Immunology (19) Metabolic Disease (4) Neurological Disease (25)

By Targets:

HDAC (90)

Histone Acetyltransferase (41)

Histone Demethylase (52)

Histone Methyltransferase (54)

Adenosine Receptor (5)

Akt (2)

Aldehyde Dehydrogenase (ALDH) (1)

Amyloid-β (2)

Antibiotic (1)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (63)

Aurora Kinase (3)

Autophagy (14)

Bacterial (5)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

Caspase (2)

CDK (3)

Cholinesterase (ChE) (4)

CMV (2)

DNA Alkylator/Crosslinker (1)

DNA Methyltransferase (4)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (12)

Epigenetic Reader Domain (17)

Estrogen Receptor/ERR (1)

Ferroptosis (3)

Fluorescent Dye (1)

Fungal (1)

GCGR (1)

Haspin Kinase (2)

HIF/HIF Prolyl-Hydroxylase (1)

HIV (1)

HSP (3)

HSV (2)

Influenza Virus (4)

Interleukin Related (4)

Keap1-Nrf2 (4)

MDM-2/p53 (5)

MicroRNA (3)

Microtubule/Tubulin (2)

Mitochondrial Metabolism (2)

Mitophagy (2)

MMP (1)

Monoamine Oxidase (2)

NF-κB (1)

Orthopoxvirus (3)

Parasite (2)

PDGFR (2)

Phosphodiesterase (PDE) (5)

PI3K (2)

PKA (3)

PKC (2)

Polo-like Kinase (PLK) (3)

PROTACs (4)

Protein Arginine Deiminase (5)

SARS-CoV (1)

Sirtuin (1)

STAT (1)

Survivin (1)

TNF Receptor (5)

Topoisomerase (1)

VD/VDR (1)

VEGFR (2)

By Research Areas:

Cancer (245)

Cardiovascular Disease (4)

Endocrinology (2)

Infection (17)

Inflammation/Immunology (19)

Metabolic Disease (4)

Neurological Disease (25)

283

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Histone Methyltransferase Histone Demethylase Histone Acetyltransferase HDAC

Cat. No.	Product Name	Target	Research Areas

HY-100734

Histone Acetyltransferase Inhibitor II	Histone Acetyltransferase	Cancer
Histone Acetyltransferase Inhibitor II (compound 2c) is a potent, selective and cell permeable *p300 histone* acetyltransferase inhibitor, with an IC₅₀** of 5 µM. Histone Acetyltransferase Inhibitor II shows anti-acetylase activity in mammalian cells.

HY-P1958

Histone H4 (2-21)
HSV Infection

Histone H4 (2-21) is the core histones associated with chromatinization of herpes simplex virus 1 (HSV-1) genomes.

Histone H4 (2-21)	HSV	Infection
Histone H4 (2-21) is the core histones associated with chromatinization of herpes simplex virus 1 (HSV-1) genomes.

HY-19348

Pimelic Diphenylamide 106 RGFA-8; TC-H 106; histone Deacetylase Inhibitor VII	HDAC	Cancer
Pimelic Diphenylamide 106 is a slow, tight-binding inhibitor of class I HDAC (HDAC 1, 2, and 3, with IC50 values of 150 nM , 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.

HY-145996

STC314	Bacterial	Infection
STC314 is a small polyanion that interact electrostatically with *histones. STC314 blocks disruption of lipid-bilayers by histones* that inhibits the cytotoxic, platelet-activating and erythrocyte-damaging effects of histones. STC314 has anti-infective effects and can be uesd for sepsis research.

HY-P3745

H1-7 (histone H1 phosphorylation site), PKA Substrate
PKA Others

H1-7 (histone H1 phosphorylation site), PKA Substrate, a synthetic polypeptide, can be used as PKA substrate.
HY-144904

MC4343
HDAC Cancer

MC4343 is a potent and dual inhibitor of EZH2 and histone deacetylase. MC4343 has the potential for the research of cancer disease.

*H1-7 (histone* H1 phosphorylation site), PKA Substrate**	PKA	Others
H1-7 (histone H1 phosphorylation site), PKA Substrate, a synthetic polypeptide, can be used as PKA substrate.

MC4343	HDAC	Cancer
MC4343 is a potent and dual inhibitor of EZH2 and histone deacetylase. MC4343 has the potential for the research of cancer disease.

HY-129039

Butyrolactone 3 MB-3	Histone Acetyltransferase	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC₅₀=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC₅₀=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases.

HY-136328

EZM0414 TFA SETD2-IN-1 TFA	Histone Methyltransferase	Cancer
EZM0414 TFA is a potent, selective and orally active inhibitor of SETD2 which is a human histone methyltransferase. EZM0414 TFA has anti-proliferative effects.

HY-135476

Depudecin (-)-Depudecin	HDAC	Cancer Neurological Disease
Depudecin ((-)-Depudecin) is a histone deacetylase (HDAC) inhibitor. Depudecin can be isolated from the fungus Alternaria brassicicola.

HY-113039

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively.

HY-W015114

L-2-Hydroxyglutaric acid disodium (S)-2-Hydroxyglutaric acid disodium	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively.

HY-W013274A

CPTH2 hydrochloride	Histone Acetyltransferase Apoptosis	Cancer
CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B).

HY-W013274

CPTH2	Histone Acetyltransferase Apoptosis	Cancer
CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B).

HY-141430

AS-85	Histone Methyltransferase	Cancer
AS-85 is a potent *ASH1L histone* methyltransferase inhibitor (IC₅₀=0.6 µM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the K_d** value of 0.78 µM.

HY-15647

BRD9539	Histone Methyltransferase	Cancer
BRD9539 is a histone methyltransferase G9a inhibitor with an IC₅₀ of 6.3 μM. BRD9539 also inhibits PRC2 activity and is inactive against SUV39H1, NSD2 and DNMT1.

HY-131970

LSD1/HDAC6-IN-1	Histone Demethylase HDAC	Cancer
LSD1/HDAC6-IN-1 is an orally active dual inhibitor of *lysine specific demethylase 1(LSD1)/Histone* deacetylase 6 (HDAC6)**, with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM).

HY-124696

PU139	Histone Acetyltransferase	Cancer
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC₅₀s of 8.39, 9.74, 2.49 and 5.35 μM, respectively.

HY-145550

Amredobresib BI894999	Epigenetic Reader Domain	Cancer
Amredobresib is a potent inhibitor of BET. Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription. Amredobresib is useful for the research of acute myeloid leukemia (AML) and cancer (extracted from patent WO2019145410A1 and WO2021175824A1).

HY-106409

Tefinostat CHR-2845	HDAC Apoptosis	Cancer
Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase (HDAC) inhibitor. Tefinostat can be cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Tefinostat can be used for the research of leukaemias.

HY-P1115

AKTide-2T	Akt	Others
AKTide-2T is an excellent in vitro substrate for AKT and shows competitive inhibition of histone H2B phosphorylation with a K_i of 12 nM. AKTide-2T mimics the optimal phosphorylation sequence of Akt and is an inhibitory peptide with the wildtype AKTide lacking Thr in the S22 position.

HY-131961

Triciferol	VD/VDR HDAC	Cancer
Triciferol functions as a multiple ligand with combined VDR agonist and HDAC antagonist activities. Triciferol binds directly to the VDR (IC₅₀=87 nM), and functions as an agonist with 1,25D-like potency on several 1,25D target genes. Triciferol induces marked tubulin hyperacetylation, and augments histone acetylation. Antiproliferative and cytotoxic activities.

HY-P1115A

AKTide-2T TFA	Akt	Others
AKTide-2T TFA is an excellent in vitro substrate for AKT and shows competitive inhibition of histone H2B phosphorylation with a K_i of 12 nM. AKTide-2T TFA mimics the optimal phosphorylation sequence of Akt and is an inhibitory peptide with the wildtype AKTide lacking Thr in the S22 position.

HY-139348

PFI-90	Histone Demethylase Apoptosis	Cancer
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).

HY-100671

L002	Histone Acetyltransferase STAT	Cancer Inflammation/Immunology
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC₅₀ of 1.98 μM. L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation. L002 has the potential for hypertension‐induced cardiac hypertrophy and fibrogenesis treatment.

HY-114566

SPV106	Histone Acetyltransferase	Metabolic Disease
SPV106 is histone acetylase (HAT) and GCN5-related N-acetyltransferases (GNAT) activator. SPV106 can be used for the research of type 2 diabetes (T2D).

HY-115926

BRD4 Inhibitor-16	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-16 (Compound 4) is a potent inhibitor of bromodomain 4 (BRD4). Overexpression of bromodomain 4 (BRD4) is closely correlated with a variety of human cancers by regulating the histone post-translational modifications. BRD4 Inhibitor-16 represents a useful tool for explorative studies of BRD4 inhibition, such as an improved understanding of BRD4 inhibitor release-related information.

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active *p300/CBP histone* acetyltransferase (HAT) inhibitor with IC₅₀** values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines.

HY-44062

G9a-IN-1	Histone Methyltransferase	Inflammation/Immunology Cancer
G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer.

HY-152235

HDAC6-IN-15	HDAC	Cancer Neurological Disease
HDAC6-IN-15 is a selective histone deacetylase 6 (HDAC6) inhibitor. HDAC6-IN-15 has potent inhibitory activity for HDAC6 with IC₅₀ value of 38.2 nM. HDAC6-IN-15 can be used for the research of cancer and neurodegenerative diseases.

HY-W017132

2,4-PDCA	Histone Demethylase	Cancer
2,4-PDCA (2,4 pyridine dicarboxylic acid) is a broad-spectrum inhibitor of 2OG oxygenase, including *JmjC domain-containing family of histone* demethylases (JHDMs)**. 2,4-PDCA is a target chemical in the field of bio-based plastics.

HY-121093

DC-S239	Histone Methyltransferase	Cancer
DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC₅₀ value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity.

HY-131035

Lys-CoA TFA	Histone Acetyltransferase	Cancer
Lys-CoA TFA is a selective p300 histone acetyltransferase (HAT) inhibitor (IC₅₀=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC₅₀=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation.

HY-146670

KDM5B-IN-3	Histone Demethylase	Cancer
KDM5B-IN-3 (Compound 5) is a histone lysine specific demethylase 5B (KDM5B/JARID1B) inhibitor with an IC₅₀ of 9.32 μM. KDM5B-IN-3 can be used for the research of gastric cancer.

HY-150586

PTG-0861	HDAC Apoptosis	Cancer
PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC₅₀ value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers.

HY-100384

NKL 22	HDAC	Neurological Disease
NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC₅₀ of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 exhibits selectivity over HDAC2/4/5/7/8 (IC₅₀≥1.59 μM). NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.

HY-13267

Droxinostat NS 41080	HDAC Apoptosis	Cancer
Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC₅₀ values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC).

HY-120046

YF479	HDAC	Cancer
YF479 is a potent inhibitor of histone deacetylase. YF479 abates cell viability, suppresses colony formation and tumor cell motility. YF479 significantly inhibits breast tumor growth and metastasis. YF479 has the potential for the research of clinical trials for breast cancer.

HY-141429C

AS-99	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent, and selective *ASH1L histone* methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis** and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo.

HY-116673

TTK21	Histone Acetyltransferase	Neurological Disease
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of adult neurogenesis and long-term memory.

HY-141429

AS-99 free base	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent and selective *ASH1L histone* methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis** and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo.

HY-W015239

KAT8-IN-1	Others	Cancer Inflammation/Immunology
KAT8-IN-1 is a lysine (K) acetyltransferase 8 (KAT8) inhibitor, with IC₅₀s of 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B), respectively. KAT8 inhibits histone acetyltransferases (HATs), and could result in disease states, such as cancer or inflammatory diseases.

HY-141429A

AS-99 TFA	Histone Methyltransferase Apoptosis	Cancer
AS-99 TFA is a first-in-class, potent and selective *ASH1L histone* methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis** and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo.

HY-13643

Daminozide	Histone Demethylase	Cancer
Daminozide, a plant growth regulator, is a selective inhibitor of the human *KDM2/7 histone* demethylases, with IC₅₀s of 0.55, 1.5 and 2.1 μM for PHF8, KDM2A, and KIAA1718**, respectively. Daminozide has >100-fold selectivity for KDM2/7 subfamily versus other demethylase subfamily members tested.

HY-114208

BI-9321	Histone Methyltransferase	Cancer
BI-9321 is a potent, selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a K_d value of 166 nM. BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC₅₀ of 1.2 μM in U2OS cells.

HY-114208A

BI-9321 trihydrochloride	Histone Methyltransferase	Cancer
BI-9321 trihydrochloride is a potent, selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a K_d value of 166 nM. BI-9321 trihydrochloride is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 trihydrochloride specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC₅₀ of 1.2 μM in U2OS cells.

HY-146750

HDAC-IN-37	HDAC Apoptosis	Cancer
HDAC-IN-37 is a potent HDAC inhibitor with IC₅₀s of 0.0551 μM, 1.24 μM, 0.948 μM and 34.2 μM for HDAC1, HDAC3, HDAC8 and HDAC6, respectively. HDAC-IN-37 induces histone acetylation in a slow-off manner. HDAC-IN-37 prevents cell transition from G1 phase to S phase and induces early cell apoptosis.

HY-116227

(2S,3R)-LP99	Epigenetic Reader Domain	Inflammation/Immunology
(2S,3R)-LP99 is a potent and selective BRD7 and BRD9 inhibitor with an K_D of 99 nM for BRD9. (2S,3R)-LP99 inhibits the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. (2S,3R)-LP99 demonstrates that BRD7/9 plays a role in regulating pro-inflammatory cytokine secretion.

HY-144098

HDAC8-IN-2	HDAC	Others
HDAC8-IN-2 (compound 5o) is a potent HDAC8 inhibitor, with IC₅₀ values of 0.27 and 0.32 μM for smHDAC8 (Schistosoma mansoni histone deacetylase 8) and hHDAC8, respectively. HDAC8-IN-2 shows significant killing of the schistosome larvae. HDAC8-IN-2 markedly impairs egg laying of adult worm pairs.

HY-144315

Snail/HDAC-IN-1	HDAC	Cancer
Snail/HDAC-IN-1 is a potent Snail/HDAC dual target inhibitor. Snail/HDAC-IN-1 displays potent inhibitory activity against HDAC1 with an IC₅₀ of 0.405 μM and potent inhibition against Snail with a K_d of 0.18 μM. Snail/HDAC-IN-1 increases histone H4 acetylation in HCT-116 cells and decreases the expression of Snail protein to induce cell apoptosis.

HY-100508

ITSA-1	HDAC	Cancer
ITSA-1 is an activator of histone deacetylase (HDAC), and counteract trichostatin A (TSA)-induced cell cycle arrest, histone acetylation, and transcriptional activation.

HY-146351

HDAC-IN-38	HDAC	Neurological Disease
HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5).

HY-111048

Corin	Histone Demethylase HDAC	Cancer
Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a K_i(inact) of 110 nM for LSD1 and an IC₅₀ of 147 nM for HDAC1.

HY-144893

OKI-006	HDAC	Cancer
OKI-006 is a potent and orally active inhibitor of histone deacetylase (HDAC). OKI-006 is a unique congener of the natural product HDAC inhibitor largazole. Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. OKI-006 has the potential for the research of cancer disease.

HY-152225

MC2625	HDAC Apoptosis	Cancer
MC2625 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2625 show selective HDAC3 and HDAC6 inhibition with IC₅₀s of 80 nM and 11 nM. MC2625 increases acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells (CSCs) growth by apoptosis induction.

HY-18362

HDAC-IN-5
HDAC Cancer

HDAC-IN-5 is a histone deacetylase (HDAC) inhibitor.
HY-12991A

BIX-01338 hydrate
Histone Methyltransferase Cancer

BIX-01338 hydrate is a histone lysine methyltransferase inhibitor.
HY-112308

NCGC00247743
Histone Demethylase Cancer

NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.

HY-123604A

TH1834 dihydrochloride	Histone Acetyltransferase Apoptosis	Cancer
TH1834 dihydrochloride is a specific *Tip60 (KAT5) histone* acetyltransferase inhibitor. TH1834 dihydrochloride induces apoptosis** and increases DNA damage in breast cancer. TH1834 dihydrochloride does not affect the activity of related histone acetyltransferase MOF. Anticancer activity.

HY-102060

WM-8014
Histone Acetyltransferase Cancer

WM-8014 is an inhibitor of MOZ, a member of histone acetyltransferases, with an IC₅₀ of 55 nM.

HY-123604

TH1834	Histone Acetyltransferase Apoptosis	Cancer
TH1834 is a specific *Tip60 (KAT5) histone* acetyltransferase (HAT) inhibitor. TH1834 induces apoptosis** and increases DNA damage in breast cancer. TH1834 does not affect the activity of related histone acetyltransferase MOF. Anticancer activity.

HY-144905

MC4355
Histone Methyltransferase HDAC Cancer

MC4355 is a dual inhibitor of EZH2 and histone deacetylase (HDAC).
HY-102059

MOZ-IN-2
Histone Acetyltransferase Cancer

MOZ-IN-2 is an inhibitor of protein MOZ, a member of histone acetyltransferases, with an IC₅₀ of 125 μM.
HY-15774A

CBB1003 hydrochloride
Histone Demethylase Cancer

CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
HY-D1397

Kbz probe 1
Fluorescent Dye Others

Kbz probe 1 serves as a versatile probe for interrogating histone benzoylation and interactions in living cells.
HY-15593

Pinometostat
EPZ-5676
Histone Methyltransferase Cancer

Pinometostat (EPZ-5676) is a potent DOT1L histone methyltransferase inhibitor with a K_i of 80 pM.
HY-15774

CBB1003
Histone Demethylase Cancer

CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
HY-124960

CTPB
Histone Acetyltransferase Cancer

CTPB is a good activator of p300 histone acetyl transferase (HAT) enzyme.
HY-143654

WW437
HDAC Cancer

WW437 is a histone deacetylase (HDAC) inhibitor with potent anti-breast cancer ability in vitro and in vivo.
HY-B0494

Bufexamac
Bufexamic acid
HDAC Inflammation/Immunology

Bufexamac is a class IIB histone deacetylases (HDAC6 and HDAC10) inhibitor used as an anti-inflammatory agent.
HY-16914

MC1568
HDAC Cancer

MC1568 is a selective class II (IIa) histone deacetylas (HDAC II) inhibitor, used for cancer research.
HY-148807

Zavondemstat
Histone Demethylase Cancer

Zavondemstat is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity.
HY-128919

Ac-Lys-AMC
HDAC Others

Ac-Lys-AMC (Hexanamide), also termed MAL, is a fluorescent substrate for histone deacetylase HDACs.

HY-122182

OTS193320	Histone Methyltransferase Apoptosis	Cancer
OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (DOX; HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX.

HY-13506

M344
D 237; MS 344
HDAC Cancer

M344 (D 237) is an inhibitor of histone deacetylase (IC₅₀=100 nM) and an inducer of terminal cell fifferentiation.
HY-107549

KD 5170
HDAC Cancer

KD 5170 is a pan inhibitor of histone deacetylases (HDACs) and exhibits broad spectrum antitumor activity in vitro and in vivo.
HY-103085

T-3775440 hydrochloride
Histone Demethylase Cancer

T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase (LSD1) inhibitor with an IC₅₀ value of 2.1 nM.
HY-115761

Dihydrochlamydocin
HDAC Cancer

Dihydrochlamydocin is a histone deacetylases (HDAC) inhibitor. Dihydrochlamydocin shows strong cytostatic activity towards mastocytoma cells.
HY-19772

HDAC-IN-3
HDAC Cancer

HDAC-IN-3 is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2008040934 A1.

HY-116818

Crebinostat	HDAC	Neurological Disease
Crebinostat is a potent histone deacetylase (HDAC) inhibitor with IC₅₀ values of 0.7 nM, 1.0 nM, 2.0 nM and 9.3 nM for HDAC1, HDAC2, HDAC3 and HDAC6, respectively. Crebinostat potently induces acetylation of both histone H3 and histone H4 as well as enhances the expression of the cAMP response element-binding protein (CREB) target gene Egr1. Crebinostat increases the density of synapsin-1 punctae along dendrites in cultured neurons. Crebinostat can modulate chromatin-mediated neuroplasticity and exhibits enhanced memory in mice.

HY-121493

TM2-115
Histone Methyltransferase Parasite Infection

TM2-115 inhibits malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death.

HY-108706

KDM2A/7A-IN-1	Histone Demethylase	Cancer
KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC₅₀ of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases.

HY-13823

C646	Histone Acetyltransferase Autophagy Epigenetic Reader Domain Apoptosis	Cancer
C646 is a selective and competitive histone acetyltransferase p300 inhibitor with K_i of 400 nM, and is less potent for other acetyltransferases.

HY-151248

HDAC2-IN-1	HDAC	Neurological Disease
HDAC2-IN-1 (Compound 17) is a brain penetrant, orally active, competitive HDAC2 inhibitor with an IC₅₀ of 0.5 μM. HDAC2-IN-1 also inhibits HDAC1 and HDAC8 with IC₅₀s of 1.61 μM and 0.98 μM, respectively.

HY-114209

MRK-740	Histone Methyltransferase	Cancer
MRK-740 is a potent, selective and substrate-competitive *PRDM9 histone* methyltransferase inhibitor with an IC₅₀ of 80 nM. MRK-740 is more selective for PRDM9** than other histone methyltransferases and other non-epigenetic targets. MRK-740 reduces PRDM9-dependent trimethylation of H3K4 (IC₅₀ = 0.8 µM).

HY-139626

EPZ-719
Histone Methyltransferase Cancer

EPZ-719 is a novel and potent SETD2 inhibitor ( IC₅₀ = 0.005 μM) with a high selectivity over other histone methyltransferases.
HY-138945

SYY-B085-1
Histone Acetyltransferase Cancer

SYY-B085-1 is a histone acetyltransferase (HAT) inhibitor extracted from patent WO2019201291A1.

HY-N6735

Apicidin OSI 2040	HDAC Parasite	Cancer Infection
Apicidin (OSI 2040) is a fungal metabolite, acts as a histone deacetylase (HDAC) inhibitor, with antiparasitic activity and a broad spectrum antiproliferative activity.

HY-143442

CBP/p300-IN-18	Histone Acetyltransferase	Cancer
CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively.

HY-143440

CBP/p300-IN-16	Histone Acetyltransferase	Cancer
CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively.

HY-143441

CBP/p300-IN-17
Histone Acetyltransferase Cancer

CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively.

HY-A0298

EZH2-IN-2	Histone Methyltransferase	Cancer
EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC₅₀ of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity.

HY-112804

SGC-iMLLT	Epigenetic Reader Domain	Cancer
SGC-iMLLT is a first-in-class chemical probe and a potent, selective inhibitor of MLLT1/3-histone interactions with an IC₅₀ of 0.26 μM. SGC-iMLLT shows high binding activity towards MLLT1 YEATS domain (YD) and MLLT3 YD (AF9/YEATS3) with K_ds of 0.129 and 0.077 μM, respectively.

HY-122746

E67-2	Histone Methyltransferase	Cancer
E67-2, as the E67 derivative, is a low-toxicity, selective KIAA1718 Jumonji domain inhibitor with an IC₅₀ value of 3.4 µM. E67-2 selectively inhibits histone H3 lysine 9 (H3K9) Jumonji demethylase as well as histone H3 lysine 4 (H3K4) demethylase.

HY-P0324

Parasin I
Bacterial Infection

Parasin I is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity.
HY-13432

Nanatinostat
CHR-3996
HDAC Cancer

Nanatinostat (CHR-3996) is a potent, class I selective and orally active histone deacetylase (HDAC) inhibitor with an IC₅₀ of 8 nM.

HY-B0809S

Theophylline-d6 1,3-Dimethylxanthine-d₆; Theo-24-d₆	Adenosine Receptor Phosphodiesterase (PDE) Autophagy Endogenous Metabolite	Cancer
Theophylline-d₆ is the deuterium labeled Theophylline. Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.

HY-16138

Ivaltinostat CG-200745	HDAC MDM-2/p53 Apoptosis	Cancer
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects.

HY-139560

KDM2B-IN-1
Histone Demethylase Cancer Inflammation/Immunology

KDM2B-IN-1 is a histone demethylase (kdm2b) inhibitor and can be used for hyperproliferative diseases research.
HY-112445

SGC3027
Histone Methyltransferase Cancer

SGC3027 is a histone methyltransferase inhibitor. SGC3027 is the first potent, selective and cell active chemical probe for PRMT7.
HY-142093

NSD3-IN-1
Histone Methyltransferase Cancer

NSD3-IN-1 (compound B1) is an inhibitor of histone methyltransferase NSD3 with an IC₅₀ value of 28.58 μM.

HY-16138A

Ivaltinostat formic CG-200745 formic	HDAC MDM-2/p53 Apoptosis	Endocrinology Inflammation/Immunology
Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects.

HY-134964

CTB
Histone Acetyltransferase Apoptosis Cancer Neurological Disease

CTB is a potent p300 histone acetyltransferase activator. CTB can effectively induce apoptosis in MCF-7 cells.

HY-13216

Pyroxamide	HDAC Apoptosis	Cancer
Pyroxamide is a potent inhibitor of histone deacetylase 1 (HDAC1) with an ID₅₀ of 100 nM. Pyroxamide can induce apoptosis and cell cycle arrest in leukemia.

HY-112623

Vafidemstat ORY-2001	Histone Demethylase Monoamine Oxidase	Neurological Disease
Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.

HY-19612B

DDP-38003 trihydrochloride	Histone Demethylase	Cancer
DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM.

HY-111390

Dot1L-IN-2	Histone Methyltransferase	Cancer
Dot1L-IN-2 is a potent, selective and orally bioavailable inhibitor of Dot1L (a histone methyltransferase), with an IC₅₀ and K_i of 0.4 nM and 0.08 nM, respectively.

HY-B1941

4-tert-Octylphenol	Endogenous Metabolite Apoptosis	Endocrinology Neurological Disease
4-tert-Octylphenol, a endocrine-disrupting chemical, is an estrogenic agent. 4-tert-Octylphenol induces apoptosis in neuronal progenitor cells in offspring mouse brain. 4-tert-Octylphenol reduces bromodeoxyuridine (BrdU), mitotic marker Ki67, and phospho-histone H3 (p-Histone-H3), resulting in a reduction of neuronal progenitor proliferation. 4-tert-Octylphenol disrupts brain development and behavior in mice.

HY-N0005

Curcumin Diferuloylmethane; Natural Yellow 3; Turmeric yellow	Histone Acetyltransferase Epigenetic Reader Domain Keap1-Nrf2 Autophagy Mitophagy Influenza Virus Ferroptosis	Cancer
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

HY-P0324A

Parasin I TFA
Bacterial Infection

Parasin I (TFA) is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity.

HY-100757

CPUY074020	Histone Methyltransferase	Cancer
CPUY074020 is a potent and oral bioavailable inhibitor of histone methyltransferase G9a, with an IC₅₀ of 2.18 μM. CPUY074020 possesses anti-proliferative activity.

HY-100365

Remetinostat SHP-141	HDAC	Cancer
Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma.

HY-15489

Scriptaid Scriptide; GCK1026	HDAC Autophagy Apoptosis Influenza Virus	Cancer
Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment.

HY-145813

MU1656	Histone Methyltransferase	Cancer
MU1656 is a potent and selective inhibitor of histone methyltransferase DOT1L, with an IC₅₀ of 2 nM. MU1656 can be used for the research of hematological malignancies.

HY-152226

MC2590	HDAC Apoptosis	Cancer
MC2590 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2590 is a inhibitor of HDAC1-3, -6, -8, and -10 (class I/IIb-selective inhibitor) with IC₅₀s of 0.015 μM-0.156 μM. MC2590 also inhibits HDAC isoforms HDAC4, HDAC5, HDAC7, HDAC9, HDAC11 with IC₅₀s of 1.35 μM-3.98 μM. MC2625 induces G2/M cell cycle arrest and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction.

HY-18361

TMP195
HDAC Cancer

TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor with K_is of 59, 60, 26, 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

HY-50934

Tacedinaline N-acetyldinaline; CI-994; Goe-5549	HDAC Apoptosis	Cancer
Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC₅₀s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.

HY-147230

EZH2-IN-13	Histone Methyltransferase	Cancer
EZH2-IN-13 is a potent EZH2 inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity.

HY-16305

Maribavir 1263W94; BW1263W94; GW257406X	CMV	Infection
Maribavir is a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, with an IC₅₀ of 3 nM. Maribavir has potent antiviral activity against HCMV and Epstein-Barr virus (EBV).

HY-101928

KDM4D-IN-1
Histone Demethylase Cancer

KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC₅₀ value of 0.41±0.03 μM.

HY-19612A

DDP-38003 dihydrochloride	Histone Demethylase	Cancer
DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM.

HY-121095

Bizine	Histone Demethylase	Cancer Neurological Disease
Bizine, a Phenelzine analogue, is a potent and selective LSD1 inhibitor, with a b>K_i of 59 nM. Bizine can modulate bulk histone methylation in cancer cells. Bizine shows neuroprotective effects.

HY-19980A

PRIMA-1 NSC-281668	Autophagy MDM-2/p53 Ferroptosis Apoptosis	Cancer
PRIMA-1 (NSC-281668) is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.

HY-18935A

CBL0137 hydrochloride Curaxin-137 hydrochloride; CBL-C137 hydrochloride	MDM-2/p53 NF-κB	Cancer
CBL0137 hydrochloride is an inhibitor of the histone chaperone, FACT. CBL0137 hydrochloride can also activate p53 and inhibits NF-κB with EC₅₀s of 0.37 and 0.47 µM, respectively.

HY-16705

BRD4770	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of *lysine 9 on histone* H3 (H3K9) with an EC₅₀** of 5 µM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence.

HY-18360

TMP269	HDAC	Cancer
TMP269 is a novel and selective class IIa histone deacetylase (HDAC) inhibitor with IC₅₀s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

HY-N2020

Anacardic Acid Hydroginkgolic acid; Ginkgolic Acid C15:0	Histone Acetyltransferase Epigenetic Reader Domain Bacterial	Cancer
Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀s of ∼8.5 μM and ∼5 μM, respectively.

HY-15217

CHR-6494	Haspin Kinase	Cancer
CHR-6494 is a potent inhibitor of haspin, with an IC₅₀ of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer.

HY-N1988

Cucurbitacin IIa Hemslecin A	Survivin Apoptosis	Cancer
Cucurbitacin IIa is a triterpene isolated from Hemsleya amalils Diels, induces apoptosis of cancer cells, reduces expression of survivin, reduces phospho-Histone H3 and increases cleaved PARP in cancer cells.

HY-N2019

Chaetocin	Histone Methyltransferase Bacterial Antibiotic	Cancer Infection
Chaetocin is a specific inhibitor of the histone methyltransferase (HMT) SU(VAR)3-9 with an IC₅₀ of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (TrxR) with an IC₅₀ of 4 μM.

HY-128876

CBP/p300-IN-3
Histone Acetyltransferase Cancer

CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1.
HY-145613

5-Phenylpentan-2-one
HDAC Metabolic Disease

5-Phenylpentan-2-one is a potent histone deacetylases (HDACs) inhibitor. 5-Phenylpentan-2-one can be used for urea cycle disorder research.

HY-128918

SIS17	HDAC	Others
SIS17 is a mammalian histone deacetylase 11 (HDAC 11) inhibitor with an IC₅₀ value of 0.83 μM, inhibits the demyristoylation HDAC11 substrate, serine hydroxymethyl transferase 2, without inhibiting other HDACs.

HY-109109

Alteminostat CKD-581	HDAC Apoptosis	Cancer
Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research.

HY-135128

Dot1L-IN-5
Histone Methyltransferase Cancer

Dot1L-IN-5 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC₅₀ of 0.17 nM.
HY-135127

Dot1L-IN-4
Histone Methyltransferase Cancer

Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC_{50 SPA DOT1L} of 0.11 nM.

HY-15433A

Quisinostat dihydrochloride JNJ-26481585 dihydrochloride	HDAC Apoptosis Autophagy	Cancer
Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally available, potent pan-HDAC inhibitor with IC₅₀s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity.

HY-135129

Dot1L-IN-6
Histone Methyltransferase Cancer

Dot1L-IN-6 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC_{50 SPA DOT1L} of 0.19 nM.

HY-15433

Quisinostat JNJ-26481585	HDAC Apoptosis Autophagy	Cancer
Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC₅₀ values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity. Quisinostat can induce autophagy in neuroblastoma cells.

HY-17447B

(1S,2R)-Tranylcypromine hydrochloride (1S,2R)-SKF 385 hydrochloride	Monoamine Oxidase Histone Demethylase	Neurological Disease
(1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits MAO and LSD1.

HY-13808

UNC 0631	Histone Methyltransferase	Cancer
UNC 0631 is a potent histone methyltransferase G9a inhibitor with an IC₅₀ of 4 nM. UNC 0631 potently reduces H3K9me2 levels in MDA-MB-231 cells with an IC₅₀ of 25 nM.

HY-107455

A-485	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
A-485 is a potent and selective catalytic inhibitor of p300/CBP with IC₅₀s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively.

HY-12310

RSC133	DNA Methyltransferase HDAC	Others
RSC133 exhibits dual activity by inhibiting histone deacetylase and DNA methyltransferase. RSC133 effectively facilitates reprogramming of human somatic cells to pluripotent stem cells and supports the maintenance of an undifferentiated state of human pluripotent stem cells.

HY-10442

3-Deazaneplanocin A DZNep; 3-Deazaneplanocin	Histone Methyltransferase Orthopoxvirus	Cancer Infection
3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity.

HY-112316

BAY1238097	Epigenetic Reader Domain	Cancer
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC₅₀ <100 nM).

HY-128875

CBP/p300-IN-10	Histone Acetyltransferase	Cancer
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC₅₀ values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer.

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active *EP300/CBP histone* acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT**. CPI-1612 has an anticancer activity.

HY-19328

ACY-775	HDAC	Neurological Disease Cardiovascular Disease
ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC₅₀ of 7.5 nM. ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-15273

UNC0638	Histone Methyltransferase Autophagy Influenza Virus	Cancer Infection
UNC0638 selectively inhibits G9a and *GLP histone* methyltransferase activity with IC₅₀s of less than 15 nM and 19 nM, respectively. UNC0638 has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus)** activities.

HY-120290

PU141	Histone Acetyltransferase	Cancer
PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and p300. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity.

HY-114303

CM-675	Phosphodiesterase (PDE) HDAC	Neurological Disease
CM-675 is a dual phosphodiesterase 5 (PDE5) and *class I histone* deacetylases-selective inhibitor, with IC₅₀** values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675 has potential to treat Alzheimer’s disease.

HY-113038B

α-Hydroxyglutaric acid 2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases.

HY-139601

KDM2B-IN-4	Histone Demethylase	Cancer
KDM2B-IN-4 is a histone demethylase KDM2B inhibitor extracted from patent WO2016112284A1, compound 182b. KDM2B-IN-4 can be used for the research of cancer.

HY-100132

CBP/p300-IN-5	Histone Acetyltransferase	Cancer
P300/CBP-IN-5 is a potent *p300/CBP histone* acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC₅₀** of 18.8 nM.

HY-P1733

BMf-BH3	Apoptosis	Cancer
BMf-BH3 belongs to the Bcl-2 apoptosis mediator family. BH3-only protein, Bmf is a key molecule for histone deacetylase (HDAC) inhibitors mediated enhancing effect on ionizing radiation-induced cell death.

HY-13322

Pracinostat SB939	HDAC Apoptosis	Cancer
Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC₅₀s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM.

HY-139600

KDM2B-IN-3	Histone Demethylase	Cancer
KDM2B-IN-3 is a histone demethylase KDM2B inhibitor extracted from patent WO2016112284A1, compound 183c. KDM2B-IN-3 can be used for the research of cancer.

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts. Malantide TFA is also an efficient substrate for PKC with a K_m of 16 μM.

HY-P1597

Malantide	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts. Malantide is also an efficient substrate for PKC with a K_m of 16 μM.

HY-118672

HNHA	HDAC MMP HIF/HIF Prolyl-Hydroxylase	Cancer
HNHA is a potent histone deacetylase (HDAC) inhibitor. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer.

HY-113038A

α-Hydroxyglutaric acid disodium 2-Hydroxyglutarate disodium; 2-Hydroxyglutaric acid disodium; 2-Hydroxypentanedioic acid disodium	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases.

HY-12186

3-Deazaneplanocin A hydrochloride DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Histone Methyltransferase Orthopoxvirus	Cancer Infection
3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) is a potent histone methyltransferase EZH2 inhibitor. 3-Deazaneplanocin A hydrochlorideis a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A hydrochloride also has anti-orthopoxvirus and anti-variola activities.

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas.

HY-12186G

3-Deazaneplanocin A hydrochloride DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Histone Methyltransferase Orthopoxvirus	Cancer Infection
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor.

HY-100859

LSD1-IN-5	Histone Demethylase	Cancer
LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.

HY-13953

JIB-04	Histone Demethylase Apoptosis	Cancer
JIB-04 is a pan-selective *Jumonji histone* demethylase inihibitor with IC₅₀**s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

HY-100860

LSD1-IN-6	Histone Demethylase	Cancer
LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.

HY-139561

KDM2B-IN-2	Histone Demethylase	Cancer Inflammation/Immunology
KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC₅₀ of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases research.

HY-139149

NiCur	Histone Acetyltransferase	Cancer
NiCur is a potent and selective *CBP histone* acetyltransferase (HAT) inhibitor with an IC₅₀ value of 0.35 μΜ. NiCur, which blocks CBP HAT** activity and downregulates p53 activation upon genotoxic stress. NiCur can be used for performing mechanistic studies without affecting the expression of target proteins.

HY-115475

SW-100	HDAC	Neurological Disease
SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC₅₀ of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier.

HY-N2345

Procyanidin B3	Histone Acetyltransferase	Cancer
Procyanidin B3 is a natural product, acts as a specific HAT inhibitor, binds to the other site of p300 instead of the active site, selectively inhibits p300-mediated androgen receptor acetylation. Procyanidin B3 has no effect on HDAC or HMT (histone methyltransferase).

HY-147290

NSC 694623	Histone Acetyltransferase	Cancer
NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC₅₀ value of 15.9 μM for recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has antiproliferative activity against certain cancer cells. NSC 694623 can be used for researching anticancer.

HY-N0005S

Curcumin-d6 Diferuloylmethane-d₆; Natural Yellow 3-d₆; Turmeric yellow-d₆	Keap1-Nrf2 Ferroptosis Autophagy Histone Acetyltransferase Epigenetic Reader Domain Mitophagy Influenza Virus	Infection Metabolic Disease Inflammation/Immunology
Curcumin-d₆is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.

HY-151364

HDAC6/8/BRPF1-IN-1	HDAC	Cancer
HDAC6/8/BRPF1-IN-1 is a dual inhibitor of both HDAC6/8 and the bromodomain and PHD finger containing protein 1 (BRPF1). HDAC6/8/BRPF1-IN-1 has inhibitory activity for HDAC1, HDAC6 and HDAC8 with IC₅₀ values of 797 nM, 344 nM and 908 nM, respectively. HDAC6/8/BRPF1-IN-1 has inhibitory activity for BRPF1 with an K_d value of 175.2 nM. HDAC6/8/BRPF1-IN-1 can be used for the research of cancer.

HY-107842

(Z)-JIB-04
NSC693627
Others Cancer

(Z)-JIB-04 (NSC693627) is the Z isomer of JIB-04 that has two forms, E (HY-13953) and Z isomers. (Z)-JIB-04 is inactive in epigenetic analysis.

HY-136557A

PAD2-IN-1 hydrochloride	Protein Arginine Deiminase	Cancer Inflammation/Immunology
PAD2-IN-1 hydrochloride, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. PAD2-IN-1 hydrochloride shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold).

HY-100748

Zabadinostat CXD101	HDAC	Cancer
Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC₅₀s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity.

HY-136557

PAD2-IN-1	Protein Arginine Deiminase	Cancer Inflammation/Immunology
PAD2-IN-1, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. PAD2-IN-1 shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold).

HY-138691A

JQKD82 trihydrochloride JADA82 trihydrochloride; PCK82 trihydrochloride	Histone Demethylase	Cancer
JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma.

HY-138691

JQKD82 JADA82; PCK82	Histone Demethylase	Cancer
JQKD82 (JADA82) is a cell-permeable and selective KDM5 inhibitor. JQKD82 increases H3K4me3 and can be used for the research of multiple myeloma.

HY-18643

TZ9	E1/E2/E3 Enzyme Apoptosis	Cancer
TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis, and inhibits the proliferation and migration of metastatic human breast cancer cells.

HY-16531A

YF-2 hydrochloride	Histone Acetyltransferase	Cancer Neurological Disease
YF-2 hydrochloride is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC₅₀s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease.

HY-146684

HDAC-IN-36	HDAC Autophagy Apoptosis	Cancer
HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC₅₀ of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research.

HY-122936

Tanshindiol C	Histone Methyltransferase Keap1-Nrf2 Sirtuin	Cancer Cardiovascular Disease
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone Methyltransferase) inhibitor with an IC₅₀ of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research.

HY-16706A

Remodelin hydrobromide	Histone Acetyltransferase	Cancer
Remodelin, a specific inhibitor of N-acetyltransferase NAT10, can ameliorate Hutchinson-Gilford Progeria Syndrom (HGPS) cellular phenotypes. Remodelin acts in a progerin- and FTI-independent pathway, by targeting and inhibiting NAT10. NAT10 is a protein with histone acetylation activity and primarily identified to be involved in regulation of telomerase activity.

HY-16531

YF-2	Histone Acetyltransferase	Cancer Neurological Disease
YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC₅₀s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease.

HY-10930

UNC0321	Histone Methyltransferase GCGR Apoptosis	Cancer
UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 63 pM and with assay-dependent IC₅₀ values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC₅₀ values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications.

HY-112316A

(R)-BAY1238097	Epigenetic Reader Domain	Cancer
(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome.

HY-110127

NU9056	Histone Acetyltransferase Apoptosis	Cancer
NU9056 is a potent and selective *Tip60 (KAT5) histone* acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis** of prostate cancer cells.

HY-13755

Sulforaphane	HDAC Keap1-Nrf2 Apoptosis	Cancer Inflammation/Immunology
Sulforaphane is an isothiocyanate present naturally in widely consumed vegetables. Sulforaphane increases tumor suppressor protein transcription and inhibits histone deacetylase activity. Sulforaphane activates Nrf2 and inhibits high glucose-induced progression of pancreatic cancer via AMPK dependent signaling. Sulforaphane has shown anti-cancer and anti-inflammatory activities.

HY-110350

CHR-6494 TFA	Haspin Kinase	Cancer
CHR-6494 TFA is a potent inhibitor of haspin, with an IC₅₀ of 2 nM. CHR-6494 TFA inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer.

HY-145818

JPS035	HDAC PROTACs	Cancer
JPS035 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS035 degrades class I histone deacetylase (HDAC). JPS035 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

HY-145816

JPS016	HDAC PROTACs	Cancer
JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

HY-145819

JPS036	HDAC PROTACs	Cancer
JPS036 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS036 degrades class I histone deacetylase (HDAC). JPS036 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

HY-145815

JPS014	HDAC PROTACs	Cancer
JPS014 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 degrades class I histone deacetylase (HDAC). JPS014 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

HY-101451

PBIT	Histone Demethylase	Cancer
PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes. PBIT inhibits JARID1B (KDM5B or PLU1) histone demethylase with an IC₅₀ of about 3 μM . PBIT also inhibits JARID1A and JARID1C with IC₅₀s of 6 μM and 4.9 μM, respectively.

HY-115974

GRPR antagonist-1	Others	Cancer
GRPR antagonist-1 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC₅₀ of 4.97, 4.36 and 3.40 μM in PC3, Pan02 and HGC-27 cells, respectively). GRPR antagonist-1 inhibits HGC-27 cell viability by decreasing the Bcl-2 level and increasing the Bax level, causing apoptosis. Anticancer activity.

HY-18712

BG45	HDAC Apoptosis Caspase	Cancer
BG45 is a potent HDAC3 inhibitor with IC₅₀ values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis.

HY-145851

Top/HDAC-IN-1	HDAC Topoisomerase Apoptosis	Cancer
Top/HDAC-IN-1 (Compound 29b) is a topoisomerase/HDAC dual inhibitor with IC₅₀s of 18, 230, 790, 87, and 5250 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, respectively. Top/HDAC-IN-1 exhibits potent antitumor activities against the HCT116 cell line with the IC₅₀ of 180 nM. Top/HDAC-IN-1 efficiently induces apoptosis with G2 cell cycle arrest in HCT116 cells.

HY-13593

Chlorambucil CB-1348; WR-139013	DNA Alkylator/Crosslinker	Cancer
Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease.

HY-115975

GRPR antagonist-2	Others	Cancer
GRPR antagonist-2 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC₅₀ of 0.77 and 2.5 μM in HGC-27 and Pan02 cells, respectively). Anticancer activity.

HY-111784

Inobrodib CCS1477	Epigenetic Reader Domain	Cancer
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression.

HY-125244

LEM-14-1189	Histone Methyltransferase	Cancer
LEM-14-1189, a LEM-14 (HY-114340) derivative, is a NSDs inhibitor with IC₅₀s of 418 μM (NSD1), 111 μM (NSD2), and 60 μM (NSD3), respectively. The NSDs, histone lysine methyltransferases (HMTases), are oncoproteins, drivers of a number of tumors. LEM-14-1189 can be used for multiple myeloma (MM) research.

HY-111544

EML741	Histone Methyltransferase	Cancer
EML741 is a histone lysine methyltransferase G9a/GLP inhibitor, with an IC₅₀ of 23 nM, K_d of 1.13 μM for G9a. EML741 also inhibits DNMT1 (IC₅₀, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated.

HY-12725

ML324	Histone Demethylase HSV CMV	Cancer
ML324 is a potent JMJD2 demethylase inhibitor with antiviral activity. ML324 also exhibits inhibition for the histone demethylase KDM4B, with an IC₅₀ of 4.9 μM. ML324 has potent anti-viral activity against both herpes simplex virus (HSV) and human cytomegalovirus (hCMV) infection via inhibition viral IE gene expression.

HY-117709

BRD6688	HDAC	Neurological Disease
BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model.

HY-100719

BRD-6929	HDAC HIV	Infection Cardiovascular Disease
BRD-6929 is a potent, selective brain-penetrant inhibitor of class I histone deacetylase HDAC1 and HDAC2 inhibitor with IC₅₀ of 1 nM and 8 nM, respectively. BRD-6929 shows high-affinity to HDAC1 and HDAC2 with K_i of 0.2 and 1.5 nM, respectively. BRD-6929 can be used for mood-related behavioral model research.

HY-100201

A-196	Histone Methyltransferase	Cancer
A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 with IC₅₀ values of 25 nM and 144 nM, respectively. A-196 inhibits SUV4-20 biochemically in a substrate-competitive manner. A-196 represents a first-in-class chemical probe of SUV4-20 to investigate the role of histone methyltransferases in genomic integrity.

HY-150249

GSK3735967	DNA Methyltransferase	Cancer
GSK3735967 is an selective, reversible, non-nucleoside inhibitor of DNMT1 with an IC₅₀ value of 40 nM. GSK3735967 contains a planar dicyanopyridine core that can specifically embed DNMT1 bound hemimethylated CpG dinucleotides. GSK3735967 has three binding sites, one of which can bind to histone H4K20me3.

HY-113038AS

α-Hydroxyglutaric acid-13C5 disodium 2-Hydroxyglutarate-¹³C₅ disodium; 2-Hydroxyglutaric acid-¹³C₅ sodium; 2-Hydroxypentanedioic acid-¹³C₅ disodium	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid-¹³C₅ (sodium) is the ¹³C labeled α-Hydroxyglutaric acid sodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) sodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid sodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-15149

Romidepsin FK 228; FR 901228; NSC 630176	HDAC Apoptosis	Cancer
Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis.

HY-132197

CBP/p300-IN-12	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and CBP inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450.

HY-118783

2-Hexyl-4-pentynoic acid (±)-2-Hexyl-4-pentynoic acid	HDAC HSP	Neurological Disease
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of HDAC inhibition (IC₅₀=13 µM) and HSP70 induction. Potent neuroprotective effects. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons.

HY-12037A

Rigosertib ON-01910	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle. Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM.

HY-120400

KDM5-C70	Histone Demethylase	Cancer
KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-*KDM5 histone* demethylase** inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels.

HY-15221

Methylstat	Apoptosis Histone Demethylase MDM-2/p53	Cancer Cardiovascular Disease
Methylstat is a potent histone demethylases inhibitor. Methylstat shows anti-proliferative activity with low cytotoxicity. Methylstat induces apoptosis and cell cycle arrest at G0/G1 phase. Methylstat increases the expression of p53 and p21 protein levels. Methylstat inhibits angiogenesis induced by various cytokines. Methylstat can be used as a chemical probe for addressing its role in angiogenesis.

HY-10929

UNC0224	Histone Methyltransferase	Cancer
UNC0224 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 2.6 nM, an IC₅₀ of 15 nM and a K_d of 23 nM. UNC0224 also potently inhibits b>GLP with assay-dependent IC₅₀ values of 20-58 nM. UNC0224 is inactive against SET7/9, SET8/PreSET7, PRMT3 and JMJD2E.

HY-113038AS1

α-Hydroxyglutaric acid-d4 disodium 2-Hydroxyglutarate-d₄ disodium; 2-Hydroxyglutaric acid-d₄ disodium; 2-Hydroxypentanedioic acid-d₄ disodium	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid-d₄ (disodium) is the deuterium labeled α-Hydroxyglutaric acid disodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-146285

LSD1-IN-20	Histone Demethylase Histone Methyltransferase	Cancer
LSD1-IN-20 (compound 1) is a potent dual non-covalent LSD1/G9a inhibitor, with K_i values of 0.44 and 0.68 μM, respectively. LSD1-IN-20 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.51 and 1.60 μM, respectively.

HY-117374

HDAC3-IN-1
HDAC Cancer

HDAC3-IN-1 (compound 5) is a potent and selective HDAC3 inhibitor, with an IC₅₀ of 5.96 nM.

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research.

HY-19553

LP99	Epigenetic Reader Domain	Inflammation/Immunology
LP99, an epigenetic probe, is a potent and selective inhibitor of the BRD7 and BRD9 bromodomains with a K_d of 99 nM against BRD9. LP99 disrupts the binding of BRD7 and BRD9 to chromatin in cells.

HY-150503

KH-259	HDAC	Neurological Disease
KH-259 (compound 1) is a potent, selective and CNS-penetrant HDAC6 inhibitor, with an IC₅₀ of 0.26 μM. KH-259 has antidepressant effects in mice through the inhibition of HDAC6 in the brain. KH-259 can be used for neurodegenerative diseases research.

HY-143443

DS17701585	Histone Acetyltransferase Histone Demethylase	Cancer
DS17701585 (Compound 11) is a highly selective, orally active EP300 and CBP inhibitor with IC₅₀ values of 0.040, 0.15, 0.45 and 0.70 µM against CBP, EP300, H3K27 and SOX2. DS17701585 can be used for cancer research.

HY-P1906

[pThr3]-CDK5 Substrate	CDK	Neurological Disease
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM.

HY-102047

KDOAM-25	Histone Demethylase	Cancer
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells.

HY-102047A

KDOAM-25 trihydrochloride	Histone Demethylase	Cancer
KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells.

HY-12037

Rigosertib sodium ON-01910 sodium	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM.

HY-150619

KDM4-IN-4	Histone Demethylase	Cancer
KDM4-IN-4 (compound 47) is a potent histone lysine demethylase 4 (KDM4) inhibitor with a modest affinity binding to ~80 μM for KDM4A-Tudor domain. KDM4-IN-4 can inhibit H3K4Me3 binding to the Tudor domain in cells with an EC₅₀ value of 105 μM. KDM4-IN-4 can be used for researching anticancer.

HY-124007

4-Iodo-SAHA ISAHA	HDAC	Cancer
4-Iodo-SAHA (1k) is an orally active class I and class II histone deacetylase (HDAC) inhibitor with EC₅₀s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM for Skbr3, HT29, U937, JA16 and HL60 cell lines, respectively. 4-Iodo-SAHA (1k) can be used for the research of cancer.

HY-16993

OICR-9429	Histone Methyltransferase Apoptosis	Cancer
OICR-9429 is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .

HY-126249

AAPK-25	Aurora Kinase Polo-like Kinase (PLK) Apoptosis	Cancer
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3^Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with K_d values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with K_d values ranging from 55-456 nM.

HY-P1906A

[pThr3]-CDK5 Substrate TFA	CDK	Neurological Disease
[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM.

HY-119939

CHDI-390576	HDAC	Cancer
CHDI-390576, a potent, cell permeable and CNS penetrant *class IIa histone* deacetylase (HDAC) inhibitor with IC₅₀**s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.

HY-152173

HDAC-IN-51	HDAC Apoptosis Bcl-2 Family CDK	Cancer
HDAC-IN-51 is a potent histone deacetylase (HDAC) inhibitor with IC₅₀ values of 0.32, 0.353, 0.431, 0.515, and 85.4 μM for HDAC10, HDAC1, HDAC2, HDAC3 and HDAC11, respectively. HDAC-IN-51 induces cell cycle arrest and apoptosis, modulating cell cycle-/apoptosis-related miRNAs expression. HDAC-IN-51 can be used in research of cancer.

HY-148458

EZH2-IN-14	Histone Methyltransferase	Cancer
EZH2-IN-14 is a selective EZH2 (Histone Methyltransferase) inhibitor with an IC₅₀ of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1.

HY-13807

UNC0646	Histone Methyltransferase	Cancer
UNC0646 is a potent and selective histone methyltransferase G9a inhibitor with an IC₅₀ of 6 nM. UNC0646 is also a potent GLP inhibitor (IC₅₀ <15 nM) and highly selective for G9a/GLP over SETD7, SUV39H2, SETD8 and PRMT3. UNC0646 reduces H3K9me2 levels in MDA-MB-231 cells with an IC₅₀ of 26 nM.

HY-102047B

KDOAM-25 citrate	Histone Demethylase	Cancer
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells.

HY-147892

HDAC-IN-42	HDAC Apoptosis	Cancer
HDAC-IN-42 (compound 14f) is a potent and selective HDAC inhibitor with IC₅₀ values of 0.19 and 4.98 µM for HDAC1 and HDAC6, respectively. HDAC-IN-42 shows anticancer and anti-proliferative activity. HDAC-IN-42 induces apoptosis and cell cycle arrest at G2/M phase.

HY-107909

Theophylline sodium glycinate 1,3-Dimethylxanthine sodium glycinate; Theo-24 sodium glycinate	Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

HY-150680

SARS-CoV-2 nsp14-IN-1	SARS-CoV Histone Methyltransferase DNA Methyltransferase	Infection
SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC₅₀ value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases.

HY-107569

Garcinol	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite	Cancer Inflammation/Immunology
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 µM and 7.39 µM, respectively. Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀ = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity.

HY-133121

WDR5-IN-1	Histone Methyltransferase Apoptosis	Cancer
WDR5-IN-1 is a potent and selective WD repeat domain 5 (WDR5) inhibitor, with a K_d of <0.02 nM. WDR5-IN-1 inhibits MLL1 histone methyltransferase (HMT) activity with an IC₅₀ of 2.2 nM. WDR5-IN-1 diminishes MYC recruitment at WDR5-displaced genes and exhibits potent anti-proliferative effects in CHP-134 (neuroblastoma) and Ramos (Burkitt’s lymphoma) lines.

HY-130538

1-Naphthohydroxamic acid	HDAC	Cancer
1-Naphthohydroxamic acid (Compound 2) is a potent and selective HDAC8 inhibitor with an IC₅₀ of 14 μM. 1-Naphthohydroxamic acid is more selectively for HDAC8 than class I HDAC1 and class II HDAC6 (IC₅₀ >100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellular HDAC activity.1-Naphthohydroxamic acid can induce tubulin acetylation.

HY-113846

CMP-5 hydrochloride	Histone Methyltransferase	Cancer
CMP-5 hydrochloride is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 hydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 hydrochloride prevents EBV-driven B-lymphocyte transformation but leaving normal B cells unaffected.

HY-120137

CMP-5	Histone Methyltransferase	Cancer
CMP-5 is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 prevents Epstein-Barr virus (EBV)-driven B-lymphocyte transformation but leaving normal B cells unaffected.

HY-107573

KDM2/7-IN-1	Histone Demethylase	Cancer
KDM2/7-IN-1 (TC-E 5002) is a selective histone demethylase KDM2/7 subfamily inhibitor (IC₅₀ values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). KDM2/7-IN-1 inhibits growth of HeLa and KYSE-150 cancer cells in vitro.

HY-123295

HDAC3-IN-T247	HDAC	Cancer Infection
HDAC3-IN-T247 is a potent and selective HDAC3 (histone deacetylase 3) inhibitor, with an IC₅₀ of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells.

HY-19554A

MM-401 TFA	Histone Methyltransferase Apoptosis	Cancer
MM-401 (TFA) is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 µM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia.

HY-16018A

Ilorasertib hydrochloride ABT-348 hydrochloride	Aurora Kinase PDGFR VEGFR	Cancer
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

HY-P2228

Chlamydocin	HDAC Apoptosis	Cancer
Chlamydocin, a fungal metabolite, is a highly potent HDAC inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin exhibits potent antiproliferative and anticancer activities. Chlamydocin induces apoptosis by activating caspase-3.

HY-143238

FY-56	Histone Demethylase	Cancer
FY-56 is a highly potent and selective LSD1/KDM1A inhibitor (IC₅₀=42 nM) and exhibits high selectivity over MAO-A/B. FY-56 induces differentiation of MOLM-13 and MV4-11 cell and has the potential for AML research.

HY-16018

Ilorasertib ABT-348	Aurora Kinase VEGFR PDGFR	Cancer
Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

HY-19554

MM-401	Histone Methyltransferase Apoptosis	Cancer
MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 µM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia.

HY-100574A

Cl-amidine hydrochloride	Protein Arginine Deiminase Apoptosis MicroRNA	Cancer Inflammation/Immunology
Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC₅₀ values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model.

HY-100574

Cl-amidine	Protein Arginine Deiminase Apoptosis MicroRNA	Cancer Inflammation/Immunology
Cl-amidine is an orally active peptidylarginine deminase (PAD) inhibitor, with IC₅₀ values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine induces apoptosis in cancer cells. Cl-amidine induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model.

HY-100014

KDM5A-IN-1	Histone Demethylase	Cancer
KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC₅₀ value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B).

HY-151153

HDAC1-IN-5	HDAC Microtubule/Tubulin Caspase Apoptosis	Cancer
HDAC1-IN-5 is a potent HDAC1 inhibitor with IC₅₀ values of 15 nM and 20 nM for HDAC1 and HDAC6, respectively. HDAC1-IN-5 can enhance the acetylation of histone H3 and α-tubulin, as well as promote the activation of caspase 3 in cancer cells, thereby inducing apoptosis. HDAC1-IN-5 induces chromatin damage by binding with DNA. HDAC1-IN-5 has strong inhibitory activity against tumor growth in xenograft mice.

HY-151443

HDAC-IN-47	HDAC	Cancer
HDAC-IN-47 is an orally active inhibitor of histone deacetylase (HDAC), with IC₅₀s of 19.75 nM (HDAC1), 5.63 nM (HDAC2), 40.27 nM (HDAC3), 57.8 nM (HDAC2), 302.73 nM (HDAC8), respectively. HDAC-IN-47 inhibits autophagy and induces apoptosis via the Bax/Bcl-2 and caspase-3 pathways. HDAC-IN-47 arrests cell cycle at G2/M phase, and shows anti-tumor efficacy in vivo.

HY-146392

HDAC-IN-39	HDAC Microtubule/Tubulin Apoptosis	Cancer
HDAC-IN-39 (compound 16c) is a potent HDAC inhibitor, with IC₅₀ values of 1.07 μM (HDAC1), 1.47 μM (HDAC2), and 2.27 μM (HDAC3), respectively. HDAC-IN-39 also significantly inhibits microtubule polymerization. HDAC-IN-39 induces cell cycle arrest at the G2/M phase. HDAC-IN-39 displays promising anticancer activity against resistant cancer cells.

HY-146678

HDAC6-IN-5	HDAC Amyloid-β Cholinesterase (ChE)	Neurological Disease
HDAC6-IN-5 (compound 11b) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC₅₀ of 0.025 μM. HDAC6-IN-5 exhibits strong inhibitory activity against Aβ_1-42 self-aggregation and AChE, with IC₅₀ values of 3.0 and 0.72 μM. HDAC6-IN-5 can enhance neurite outgrowth without significant neurotoxicity.

HY-146679

HDAC6-IN-6	HDAC Amyloid-β Cholinesterase (ChE)	Neurological Disease
HDAC6-IN-6 (compound 6a) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC₅₀ of 0.025 μM. HDAC6-IN-6 exhibits strong inhibitory activity against Aβ_1-42 self-aggregation and AChE, with IC₅₀ values of 3.0 and 0.72 μM. HDAC6-IN-6 can enhance neurite outgrowth without significant neurotoxicity.

HY-146440

LSD1/ER-IN-1	Histone Demethylase Estrogen Receptor/ERR Apoptosis	Cancer
LSD1/ER-IN-1 (compound 11g) is a potent ER and LSD1 inhibitor, with an IC₅₀ of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC₅₀ of 8.79 μM.

HY-151190

cis-4-Br-2,5-F2-PCPA S1024	Histone Demethylase	Cancer
cis-4-Br-2,5-F2-PCPA (S1024) is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a K_i value of 94 nM instead of 8.4 μM for LSD2. There is aberrant expression of LSD1 in cancer stem cells, cis-4-Br-2,5-F2-PCPA inhibits LSD1 cell proliferation and by increasing the level of dimethylated histone H3 at K4 (H3K4) in CCRF-CEM cells.

HY-B0809A

Theophylline monohydrate 1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Cancer
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

HY-B0809

Theophylline 1,3-Dimethylxanthine; Theo-24	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Cancer
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

HY-100574B

Cl-amidine TFA	Protein Arginine Deiminase Apoptosis MicroRNA	Cancer Inflammation/Immunology
Cl-amidine TFA is an orally active peptidylarginine deminase (PAD) inhibitor, with IC₅₀ values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine TFA induces apoptosis in cancer cells. Cl-amidine TFA induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine TFA prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model.

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

HY-108239

BIX-01294 trihydrochloride	Histone Methyltransferase Autophagy	Cancer
BIX-01294 trihydrochloride is a reversible and highly selective *G9a and GLP Histone* Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 trihydrochloride inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294 trihydrochloride, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy**. BIX-01294 trihydrochloride has antitumor activity in recurrent tumor cells.

HY-10587

BIX-01294	Histone Methyltransferase Autophagy	Cancer
BIX-01294 is a reversible and highly selective *G9a and GLP Histone* Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy**. BIX-01294 has antitumor activity in recurrent tumor cells.

HY-144755

MC2652	Histone Demethylase	Cancer
MC2652 (compound 1a) is a potent LSD1 inhibitor. MC2652 displays high inhibiting effects in MV4-11 and NB4 leukaemia cells. MC2652 shows antiproliferative activity against prostate cancer LNCaP cells.

HY-151532

PBRM1-BD2-IN-5	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-5 is a potent PBRM1 Bromodomain inhibitor with K_d values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5, respectively, and an IC₅₀ value of 0.26 μM for PBRM1-BD2. PBRM1-BD2-IN-5 reduces the binding of full-length PBRM1 within the PBAF complex in cell lysates to acetylated histone peptide. PBRM1-BD2-IN-5 can be used to research anticancer.

HY-12583

A-366	Histone Methyltransferase Epigenetic Reader Domain	Cancer
A-366 is a potent, highly selective, peptide-competitive histone methyltransferase G9a inhibitor with IC₅₀s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases. A-366 is also a potent, nanomolar inhibitor of the Spindlin1-H3K4me3-interaction (IC₅₀=182.6 nM). A-366 displays high affinity at human histamine H3 receptor (K_i=17 nM) and shows subtype selectivity among subsets of the histaminergic and dopaminergic receptor families.

HY-144725

HDAC1/6-IN-1	HDAC Apoptosis	Cancer
HDAC1/6-IN-1 (compound D7) is a potent multitarget inhibitor of GLP, HDAC6 and HDAC1, with IC₅₀ values of 1.3, 13, and 89 nM, respectively. HDAC1/6-IN-1 can inhibit the methylation and deacetylation of H3K9 on protein level. HDAC1/6-IN-1 induces cancer cell apoptosis, G0/G1 cell cycle arrest, and blocks migration and invasion.

HY-138097

α-NETA	Aldehyde Dehydrogenase (ALDH) Cholinesterase (ChE) Apoptosis	Cancer
α-NETA is a potent and noncompetitive choline acetyltransferase (ChA) inhibitor with an IC₅₀ of 9 μM. α-NETA is a potent ALDH1A1 (IC₅₀=0.04 µM) and chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (ChE; IC₅₀=84 µM) and acetylcholinesterase (AChE; IC₅₀=300 µM). α-NETA has anti-cancer activity.

HY-124326

Laccaic acid A	DNA Methyltransferase	Cancer
Laccaic acid A is a orally active and DNA-competitive inhibitor of DNA methyltransferase 1 (Dnmt1) (K_i=310 nM; IC₅₀=650 nM). Laccaic acid A has stronger Dnmt1 inhibitory effect than SG-1027 (HY-13962). Laccaic acid A combined with Phenethyl isothiocyanate has a strong synergistic effect on colorectal cancer.

HY-147697

LSD1-IN-21	Histone Demethylase TNF Receptor	Cancer Inflammation/Immunology
LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated LSD1 (Lysine specific demethylase-1) inhibitor, with an IC₅₀ of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity.

HY-146293

HDAC6/HSP90-IN-1	HDAC HSP	Cancer
HDAC6/HSP90-IN-1 (compound 17) is a potent and selective dual inhibitor of HDAC6 and HSP90, with IC₅₀ values of 4.3 and 46.8 nM, respectively. HDAC6/HSP90-IN-1 down-regulates PD-L1 expression in INF-γ treated H1975 lung cancer cells. HDAC6/HSP90-IN-1 inhibits tumor growth in human H1975 xenograft mice.

HY-141582

Ceramide 3 N-Stearoyl phytosphingosine	Biochemical Assay Reagents	Others
C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation.

HY-144782

HDAC10-IN-2	HDAC Autophagy	Cancer
HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells.

HY-144779

HDAC10-IN-1	HDAC Autophagy	Cancer
HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells.

HY-144694

HDAC/HSP90-IN-3	HSP HDAC Fungal	Infection
HDAC/HSP90-IN-3 (compound J5) is a potent and selective fungal Hsp90 and HDAC dual inhibitor, with IC₅₀ values of 0.83 and 0.91 μM, respectively. HDAC/HSP90-IN-3 shows antifungal activity against azole resistant C. albicans. HDAC/HSP90-IN-3 can suppress important virulence factors and down-regulate drug-resistant genes ERG11 and CDR1.

HY-146283

LSD1-IN-18	Histone Demethylase	Cancer
LSD1-IN-18 (compound 7) is a potent, non-covalent and selective LSD1 inhibitor, with K_i of 0.156 μM and K_D of 0.075 μM, respectively. LSD1-IN-18 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.16 and 0.21 μM, respectively.

HY-146284

LSD1-IN-19	Histone Demethylase	Cancer
LSD1-IN-19 (compound 29) is a potent, non-covalent and selective LSD1 inhibitor, with K_i of 0.108 μM and K_D of 0.068 μM, respectively. LSD1-IN-19 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.17 and 0.40 μM, respectively.

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library

521 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 521 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L005

Epigenetics Compound Library

1037 compounds

Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.

MCE provide a unique collection of 1037 epigenetics-related compounds that can be used in the research of the related diseases.

Cat. No.	Product Name	Type

HY-141582

Ceramide 3

N-Stearoyl phytosphingosine

Biochemical Assay Reagents

C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation.

Cat. No.	Product Name	Target	Research Area

HY-P2258

Histone H3 (1-34)	Peptides	Others
Histone H3 (1-34) is a peptide derived from human histone isotype 3.1. Histones are the main protein components of eukaryotic chromatin. Histone variants and histone modifications modulate chromatin structure, ensuring the precise operation of cellular processes associated with genomic DNA.

HY-P2557

Histone H3 (5-23)
Peptides Others

Histone H3 (5-23), derived from histone H3 5-23 amino acids, can be used as a substrate for histone acetyltransferase (HAT) assays.

HY-P2556

Histone H3 (21-44)	Peptides	Others
Histone H3 (21-44), derived from histone H3 21-44 amino acids, is usually used as a substrate (such as protein arginine methyltransferases) for methylation assays.

HY-P2509

Histone H2A (1-20)
Peptides Others

Histone H2A (1-20), a 35-residue a peptide of histone H2A, is a substrate for methyltransferase/demethylase enzymes.

HY-P2465

Histone H3 (1-35)	Peptides	Cancer
Histone H3 (1-35) is a 35-residue peptide of histone H3. Histone H3 is one of the five main histones involved in the structure of chromatin in eukaryotic cells.

HY-P2554

Histone H3 (1-25), amide	Peptides	Others
Histone H3 (1-25), amide is an N-terminal peptide fragment of histone H3. Histone H3 (1-25), amide can be used to identify the substrate for histone methyltransferases (HMTs). Histone H3 (1-25), amide, as a substrate for HMT G9a, shows more efficient than histone H3 (15-39) and full-length histone H3.

HY-P2552

Histone H3 (1-21)	Peptides	Others
Histone H3 (1-21), derived from Histone H3 1-21 amino acids, is usually used as a substrate for methyltransferase (Histone 3 K4 and K9) and acetyltransferase (Histone 3 K9 and K14) assays.

HY-P2465A

Histone H3 (1-35) (TFA)	Peptides	Cancer
Histone H3 (1-35) TFA is a 35-residue peptide of histone H3. Histone H3 is one of the five main histones involved in the structure of chromatin in eukaryotic cells.

HY-P2555

Histone H3 (23-34)	Peptides	Others
Histone H3 (23-34) is the histone H3 amino acid residues 23 to 34. Histone H3 (23-34) contains lysine residues at positions 23 and 27 that are subject to methylation and acetylation.

HY-P1958

Histone H4 (2-21)
HSV Infection

Histone H4 (2-21) is the core histones associated with chromatinization of herpes simplex virus 1 (HSV-1) genomes.
HY-P2553

Histone H3 (116-136), C116-136
Peptides Others

Histone H3 (116-136), C116-136 is a peptide spaning the C-terminus of histone H3, amino acids 116 to 136.

HY-P2480

Histone H1-derived Peptide	Peptides	Others
Histone H1-derived Peptide is a phosphopeptide and the peptide substrates containes a sequence in accordance with the optimal recognition motif for CDKs.

HY-P3931

Histone H2b(29-35)
Peptides Others

Histone H2b(29-35) is a synthetic heptapeptide that used as a substrate for cGMP-dependant kinase.

HY-P5087

Histone H3 (1-20)	Peptides	Others
Histone H3 (1-20) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P5113

Histone H3 (1-21)-Gly-Gly-Lys(biotinyl) amide	Peptides	Others
Histone H3 (1-21)-Gly-Gly-Lys(biotinyl) amide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P2257

H3K4(Me3) (1-20)	Peptides	Others
H3K4(Me3) (1-20) is a histone peptide. Trimethylation of histone H3 on lysine 4 (H3K4 me3) is found in active euchromatin but not in silent heterochromatin.

HY-P4634

*(Lys(Me)327)-Histone* H3 (21-44)-Gly-Lys(biotinyl)**	Peptides	Others
(Lys(Me)327)-Histone H3 (21-44)-Gly-Lys(biotinyl) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P3745

H1-7 (histone H1 phosphorylation site), PKA Substrate
PKA Others

H1-7 (histone H1 phosphorylation site), PKA Substrate, a synthetic polypeptide, can be used as PKA substrate.

HY-P4616

*(Lys(Ac)12)-Histone* H4 (1-21)-Gly-Gly-Lys(biotinyl)**	Peptides	Others
(Lys(Ac)12)-Histone H4 (1-21)-Gly-Gly-Lys(biotinyl) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P4620

*(Lys(Me)24)-Histone* H3 (1-21)-Gly-Gly-Lys(biotinyl)**	Peptides	Others
(Lys(Me)24)-Histone H3 (1-21)-Gly-Gly-Lys(biotinyl) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P4627

*(Lys(Me)29)-Histone* H3 (1-21)-Gly-Gly-Lys(biotinyl)**	Peptides	Others
(Lys(Me)29)-Histone H3 (1-21)-Gly-Gly-Lys(biotinyl) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P5115

*(Lys(Me,Me)27)-Histone* H3 (21-44)-Gly-Lys(Biotinyl)**	Peptides	Others
(Lys(Me,Me)27)-Histone H3 (21-44)-Gly-Lys(Biotinyl) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P4638

*(Lys(Me)39)-Histone* H3 (1-21)-Gly-Gly-Lys(biotinyl) amide**	Peptides	Others
(Lys(Me)39)-Histone H3 (1-21)-Gly-Gly-Lys(biotinyl) amide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P4636

*(Lys(Me)34)-Histone* H3 (1-21)-Gly-Gly-Lys(biotinyl) amide**	Peptides	Others
(Lys(Me)34)-Histone H3 (1-21)-Gly-Gly-Lys(biotinyl) amide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P2252

H3K27(Me) (15-34)	Peptides	Cancer
H3K27(Me) (15-34), a histone peptide, is a repressive chromatin markderived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me).

HY-P4614

*(Lys(Ac)5,8,12,16)-Histone* H4 (1-25)-Gly-Ser-Gly-Ser-Lys(biotinyl)**	Peptides	Others
(Lys(Ac)5,8,12,16)-Histone H4 (1-25)-Gly-Ser-Gly-Ser-Lys(biotinyl) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.

HY-P2256

H3K4(Me2) (1-20)
Peptides Others

H3K4(Me2) (1-20) is a histone peptide. H3K4me2 regulates the recovery of protein biosynthesis and homeostasis following DNA damage.

HY-P2255

H3K4(Me) (1-20)	Peptides	Others
H3K4(Me) (1-20), a histone peptide. H3K4me is an intricately regulated posttranslational modification, which is broadly associated with enhancers and promoters of actively transcribed genomic loci.

HY-P2253

H3K27(Me2) (15-34)	Peptides	Cancer
H3K27(Me2) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me).

HY-P2254

H3K27(Me3) (15-34)	Peptides	Cancer
H3K27(Me3) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me).

HY-P1115A

AKTide-2T TFA	Akt	Others
AKTide-2T TFA is an excellent in vitro substrate for AKT and shows competitive inhibition of histone H2B phosphorylation with a K_i of 12 nM. AKTide-2T TFA mimics the optimal phosphorylation sequence of Akt and is an inhibitory peptide with the wildtype AKTide lacking Thr in the S22 position.

HY-P0324

Parasin I
Bacterial Infection

Parasin I is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity.
HY-P0324A

Parasin I TFA
Bacterial Infection

Parasin I (TFA) is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity.

HY-P1733

BMf-BH3	Apoptosis	Cancer
BMf-BH3 belongs to the Bcl-2 apoptosis mediator family. BH3-only protein, Bmf is a key molecule for histone deacetylase (HDAC) inhibitors mediated enhancing effect on ionizing radiation-induced cell death.

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts. Malantide TFA is also an efficient substrate for PKC with a K_m of 16 μM.

HY-P1597

Malantide	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts. Malantide is also an efficient substrate for PKC with a K_m of 16 μM.

HY-P1906

[pThr3]-CDK5 Substrate	CDK	Neurological Disease
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM.

HY-P1906A

[pThr3]-CDK5 Substrate TFA	CDK	Neurological Disease
[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 µM.

HY-P2228

Chlamydocin	HDAC Apoptosis	Cancer
Chlamydocin, a fungal metabolite, is a highly potent HDAC inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin exhibits potent antiproliferative and anticancer activities. Chlamydocin induces apoptosis by activating caspase-3.

HY-19554

MM-401	Histone Methyltransferase Apoptosis	Cancer
MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 µM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia.

Cat. No.	Product Name	Target	Research Area

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas.

Cat. No.	Product Name	Target	Category

HY-135476

Depudecin (-)-Depudecin	HDAC	Structural Classification Natural Products Brassicaceae Plants Source classification Brassica campestris L.
Depudecin ((-)-Depudecin) is a histone deacetylase (HDAC) inhibitor. Depudecin can be isolated from the fungus Alternaria brassicicola.

HY-113039

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Anti-aging Source classification Endogenous metabolite
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively.

HY-13643

Daminozide	Histone Demethylase	Ketones, Aldehydes, Acids Melilotus albus Medic. ex Desr Compositae Plants Source classification Biological Pesticide Research Disease Research Fields Cancer Agricultural Research Classification of Application Fields
Daminozide, a plant growth regulator, is a selective inhibitor of the human *KDM2/7 histone* demethylases, with IC₅₀s of 0.55, 1.5 and 2.1 μM for PHF8, KDM2A, and KIAA1718**, respectively. Daminozide has >100-fold selectivity for KDM2/7 subfamily versus other demethylase subfamily members tested.

HY-N6735

Apicidin OSI 2040	HDAC Parasite	Antibiotics Structural Classification Other Antibiotics Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Apicidin (OSI 2040) is a fungal metabolite, acts as a histone deacetylase (HDAC) inhibitor, with antiparasitic activity and a broad spectrum antiproliferative activity.

HY-P0324

Parasin I	Bacterial	Natural Products Classification of Application Fields Disease Research Fields Infection Source classification Animals
Parasin I is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity.

HY-B1941

4-tert-Octylphenol	Endogenous Metabolite Apoptosis	Monophenols Phenols Endogenous metabolite Source classification Neurological Disease Disease Research Fields Classification of Application Fields Endocrinology
4-tert-Octylphenol, a endocrine-disrupting chemical, is an estrogenic agent. 4-tert-Octylphenol induces apoptosis in neuronal progenitor cells in offspring mouse brain. 4-tert-Octylphenol reduces bromodeoxyuridine (BrdU), mitotic marker Ki67, and phospho-histone H3 (p-Histone-H3), resulting in a reduction of neuronal progenitor proliferation. 4-tert-Octylphenol disrupts brain development and behavior in mice.

HY-N0005

Curcumin Diferuloylmethane; Natural Yellow 3; Turmeric yellow	Histone Acetyltransferase Epigenetic Reader Domain Keap1-Nrf2 Autophagy Mitophagy Influenza Virus Ferroptosis	Phenols Polyphenols Pigments Disease Research Fields Cancer Food Research Anti-aging Classification of Application Fields Source classification Plants Zingiberaceae Curcuma longa
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

HY-P0324A

Parasin I TFA	Bacterial	Natural Products Classification of Application Fields Disease Research Fields Infection Source classification Animals
Parasin I (TFA) is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity.

HY-N2020

Anacardic Acid Hydroginkgolic acid; Ginkgolic Acid C15:0	Histone Acetyltransferase Epigenetic Reader Domain Bacterial	Structural Classification Ketones, Aldehydes, Acids Monophenols Phenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Anacardiaceae Anacardium occidentaleL. Ginkgoaceae Ginkgo biloba
Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀s of ∼8.5 μM and ∼5 μM, respectively.

HY-N1988

Cucurbitacin IIa Hemslecin A	Survivin Apoptosis	Triterpenes Terpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Cucurbitaceae Hemsleya chinensis Cogn. ex Forbes et Hemsl.
Cucurbitacin IIa is a triterpene isolated from Hemsleya amalils Diels, induces apoptosis of cancer cells, reduces expression of survivin, reduces phospho-Histone H3 and increases cleaved PARP in cancer cells.

HY-N2019

Chaetocin	Histone Methyltransferase Bacterial Antibiotic	Alkaloid Dimers Alkaloids Structural Classification Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Chaetocin is a specific inhibitor of the histone methyltransferase (HMT) SU(VAR)3-9 with an IC₅₀ of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (TrxR) with an IC₅₀ of 4 μM.

HY-113038B

α-Hydroxyglutaric acid 2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid	Histone Demethylase Endogenous Metabolite	Nervous System Disorder Immune System Disorder Endocrine diseases Endogenous metabolite Disease markers
α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases.

HY-113038A

α-Hydroxyglutaric acid disodium 2-Hydroxyglutarate disodium; 2-Hydroxyglutaric acid disodium; 2-Hydroxypentanedioic acid disodium	Histone Demethylase Endogenous Metabolite	Structural Classification Ketones, Aldehydes, Acids
α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases.

HY-N2345

Procyanidin B3	Histone Acetyltransferase	Flavonoids Biflavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Cancer Research of Health Products Functional Molecules Source classification Plants other families
Procyanidin B3 is a natural product, acts as a specific HAT inhibitor, binds to the other site of p300 instead of the active site, selectively inhibits p300-mediated androgen receptor acetylation. Procyanidin B3 has no effect on HDAC or HMT (histone methyltransferase).

HY-122936

Tanshindiol C	Histone Methyltransferase Keap1-Nrf2 Sirtuin	Terpenoids Structural Classification Diterpenoids Labiatae Plants Hemistepta lyrata
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone Methyltransferase) inhibitor with an IC₅₀ of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research.

HY-13755

Sulforaphane	HDAC Keap1-Nrf2 Apoptosis	Natural Products Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants other families
Sulforaphane is an isothiocyanate present naturally in widely consumed vegetables. Sulforaphane increases tumor suppressor protein transcription and inhibits histone deacetylase activity. Sulforaphane activates Nrf2 and inhibits high glucose-induced progression of pancreatic cancer via AMPK dependent signaling. Sulforaphane has shown anti-cancer and anti-inflammatory activities.

HY-107569

Garcinol	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite	Structural Classification Phenols Polyphenols Guttiferae Garcinia indica Plants Inflammation/Immunology Disease Research Fields Classification of Application Fields
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 µM and 7.39 µM, respectively. Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀ = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity.

HY-B0809

Theophylline 1,3-Dimethylxanthine; Theo-24	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Alkaloids Other Alkaloids Structural Classification Camellia sinensis (L.) O. Ktze. Immune System Disorder Endogenous metabolite Disease markers Plants Source classification Theaceae Disease Research Fields Cancer Classification of Application Fields
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research.

Species:	Human (28) Virus (1) Mouse (4) Xenopus laevis (5)
Tag:	His (22) SUMO (4) T7 (1) Tag Free (13) Myc (3) GST (4) Flag (1)
Source:	HEK293 (1) Sf9 insect cells (8) E. coli (28)

Cat. No.	Product Name	Species	Source

HY-P72798

Histone H3 Protein, Human (His)
histone H3.1; histone H3
Human E. coli
HY-P72332A

Histone H3 Protein, Human (N-His)
H3C1; histone H3.1; histone H3
Human E. coli
HY-P74886

Histone H4 Protein, Human
histone H4; HIST4H4
Human E. coli
HY-P72328

H2AC4 Protein, Human
" histone H2A type 1-B/E; histone H2A.2; histone H2A/a; histone H2A/m; H2AFM"
Human E. coli
HY-P74887

Histone H1 Protein, Human (His)
histone H1.0; histone H1(0); H1-0; H1F0; H1FV
Human E. coli
HY-P72332

Histone H3 Protein, Human
H3C1
Human E. coli
HY-P72336

Histone H4 Protein, Human/Xenopus laevis
H4C1
Xenopus laevis E. coli
HY-P72330

Histone H2A Protein, Xenopus laevis
h2ac14.L
Xenopus laevis E. coli
HY-P700258

Histone-lysine N-methyltransferase SMYD3(SMYD3) Protein, Human (His-Myc)
Human E. coli
HY-P72335

Histone H3 Protein, Human (98a.a, His)
H3C1
Human E. coli
HY-P76381

HIST2H2BE Protein, Human
histone H2B type 2-E; histone H2B-GL105; H2B/q; H2BC21; H2BFQ
Human E. coli
HY-P72331

Histone H2B 1.1 Protein, Xenopus laevis
H2B1.1
Xenopus laevis E. coli
HY-P72333

Histone H3 Protein, Xenopus laevis (135a.a)
h3c8.S
Xenopus laevis E. coli
HY-P72329

H2BC11 Protein, Human
H2BC11; histone H2B type 1-J
Human E. coli
HY-P75146

HDAC4 Protein, Human (sf9)
histone deacetylase 4; HD4; HDAC4; KIAA0288
Human Sf9 insect cells
HY-P76080

SMYD3 Protein, Human (sf9, GST)
histone-lysine N-methyltransferase SMYD3; ZMYND1; ZNFN3A1
Human Sf9 insect cells
HY-P74600

RBBP4 Protein, Mouse (sf9, His)
histone-binding protein RBBP4; CAF-I p48; RBBP-4; RBAP48
Mouse Sf9 insect cells
HY-P74601

RBBP4 Protein, Human (sf9, His)
histone-binding protein RBBP4; CAF-I p48; RBBP-4; RBAP48
Human Sf9 insect cells
HY-P75144

HDAC8 Protein, Mouse (sf9, His)
histone deacetylase 8; HD8; HDAC8; HDACL1; CDA07
Mouse Sf9 insect cells
HY-P75145

HDAC8 Protein, Human (sf9, GST)
histone deacetylase 8; HD8; HDAC8; HDACL1; CDA07
Human Sf9 insect cells
HY-P76081

SMYD3 Protein, Human (HEK293, His-Flag)
histone-lysine N-methyltransferase SMYD3; ZMYND1; ZNFN3A1
Human HEK293
HY-P77218

SUV420H2 Protein, Human (His-GST)
histone-lysine N-methyltransferase KMT5C; KMT5C; PP7130
Human E. coli
HY-P72334

Histone H3 Protein, Xenopus laevis (98a.a)
H3c8.S; H3I; hist1h3g
Xenopus laevis E. coli
HY-P72262

Histone deacetylase 1/HDAC1 Protein, Human (His-SUMO)
GON 10; HD1; HDAC1; RPD3; RPD3L1
Human E. coli
HY-P75283

DOT1L Protein, Human
histone H3-K79 methyltransferase; H3-K79-HMTase; DOT1L; KIAA1814; KMT4
Human E. coli
HY-P76382

HIST3H2A Protein, Human
histone H2A type 3; H2AW; HIST3H2A
Human E. coli

HY-P70119

Histone chaperone ASF1A/ASF1A Protein, Human (T7-His) rHuhistone chaperone ASF1A/ASF1A, T7-His; histone Chaperone ASF1A; Anti-Silencing Function Protein 1 Homolog A; hAsf1; hAsf1a; CCG1-Interacting Factor A; CIA; hCIA; ASF1A	Human	E. coli

HY-P76157

ASF1B Protein, Human (sf9, His)
histone chaperone ASF1B; hAsf1b; CCG1-interacting factor A-II; CIA-II
Human Sf9 insect cells
HY-P71592

Sap130 Protein, Mouse (His)
Sap130; histone deacetylase complex subunit SAP130; 130kDa Sin3-associated polypeptide; Sin3-associated polypeptide p130
Mouse E. coli

HY-P72223

HDAC6 Protein, Human (His-SUMO) CPBHM; FLJ16239; HD 6; HD6; HDAC 6; HDAC6; HDAC6_HUMAN; histone deacetylase 6 HD6; ; histone deacetylase 6; JM 21; JM21; KIAA0901; OTTHUMP00000032398; OTTHUMP00000197663; PPP1R90; Protein phosphatase 1 regulatory subunit 90	Human	E. coli

HY-P72224

HDAC6 Protein, Human (His) CPBHM; FLJ16239; HD 6; HD6; HDAC 6; HDAC6; HDAC6_HUMAN; histone deacetylase 6 HD6; ; histone deacetylase 6; JM 21; JM21; KIAA0901; OTTHUMP00000032398; OTTHUMP00000197663; PPP1R90; Protein phosphatase 1 regulatory subunit 90	Human	E. coli

HY-P72225

HIST1H2BM Protein, Mouse (His)
H2bc14; Hist1h2bm; histone H2B type 1-M; H2B 291B
Mouse E. coli
HY-P76062

SETD7 Protein, Human (His)
histone-lysine N-methyltransferase SETD7; H3-K4-HMTase SETD7; SET7/9; KIAA1717; KMT7; SET7; SET9
Human E. coli

HY-P71707

KAT5 Protein, Human (His) 60kDa Tat interactive protein; cPLA2 interacting protein; ESA1; histone acetyltransferase HTATIP; HTATIP1; K(lysine) acetyltransferase 5; PLIP; Tat interacting protein, 60kDa; TIP; Tip60	Human	E. coli

HY-P75551

LSD1 Protein, Human (sf9, His-GST)
Lysine-specific histone demethylase 1A; KDM1A; AOF2; KDM1; KIAA0601; LSD1
Human Sf9 insect cells

HY-P71585

KDM3B Protein, Human (Myc, His-SUMO) 5qNCA; C5orf7; JHDM2B; JmjC domain containing histone demethylation protein 2B; JmjC domain-containing histone demethylation protein 2B; jmjd1b; Jumonji domain containing 1B; Jumonji domain containing protein 1B; Jumonji domain-containing protein 1B; KDM3B; KDM3B_HUMAN; KIAA1082; Lysine (K) specific demethylase 3B ; Lysine-specific demethylase 3B; NET22; Nuclear protein 5qNCA	Human	E. coli

HY-P71548

JMJD1C Protein, Human (His-SUMO-Myc) Jmjd1c; Jumonji domain containing 1C ; Jumonji domain-containing protein 1C; Probable JmjC domain-containing histone demethylation protein 2C; Thryoid receptor interacting protein; Thyroid receptor-interacting protein 8; TR-interacting protein 8; TRIP-8; TRIP8	Human	E. coli

Cat. No.	Product Name

HY-B0809S

Theophylline-d6
Theophylline-d₆ is the deuterium labeled Theophylline. Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.

HY-N0005S

Curcumin-d6
Curcumin-d₆is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.

HY-113038AS

α-Hydroxyglutaric acid-13C5 disodium

α-Hydroxyglutaric acid-¹³C₅ (sodium) is the ¹³C labeled α-Hydroxyglutaric acid sodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) sodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid sodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-113038AS1

α-Hydroxyglutaric acid-d4 disodium

α-Hydroxyglutaric acid-d₄ (disodium) is the deuterium labeled α-Hydroxyglutaric acid disodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

Cat. No.	Product Name	Application	Reactivity

HY-P80166

Histone H3 Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H3
HY-P80178

Histone H4 Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody] to Histone H4 (acetyl K5)
HY-P80157

Histone H1.0 Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H1.0
HY-P80158

Histone H1.2 Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H1.2
HY-P80163

Histone H2B Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H2B
HY-P80177

Histone H3.3 Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H3.3
HY-P80161

Histone H2A.X Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H2A.X
HY-P80162

Histone H2A.Z Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H2A.Z
HY-P80922

TriMethyl-Histone H3 (Lys27) Rabbit mAb
H3K27me3; H3 histone; HIST1H3A; histone cluster 1; H3a
Human, Rat

Rabbit Monoclonal Antibody to TriMethyl-Histone H3 (Lys27)
HY-P80167

Histone H3 (acetyl K14) Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H3 (acetyl K14)
HY-P80168

Histone H3 (acetyl K18) Mouse mAb
Human, Rat

Mouse Monoclonal Antibody to Histone H3 (acetyl K18)
HY-P80169

Histone H3 (acetyl K27) Mouse mAb
Human, Mouse, Rat

Mouse Monoclonal Antibody to Histone H3 (acetyl K27)
HY-P80170

Histone H3 (acetyl K56) Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to to Histone H3 (acetyl K56)
HY-P80179

Histone H4 (acetyl K16) Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H4 (acetyl K16)
HY-P80180

Histone H4 (acetyl K8) Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H4 (acetyl K8)
HY-P80182

Histone H4(acetyl K5) Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H4(acetyl K5)
HY-P80643

DiMethyl-Histone H3 (YP6003) (5F6) Mouse mAb
H3K27me2; H3 histone; HIST1H3A; histone cluster 1; H3a
Human, Mouse, Rat

Mouse Monoclonal Antibody to DiMethyl-Histone H3 (Lys27)

HY-P80706

Histone H2B (YP6085) Mouse mAb H2BK5ac; H2B 1A; H2B; H2B histone family; H2B2f; H2Ba; H2Bf; HIST2H2BF; histone H2B; histone H2B type 1; histone H2B type 2-F		Human, Mouse, Rat
Mouse Monoclonal Antibody to Histone H2B

HY-P80156

Histone H1 (Mono Methyl Lys25) Mouse mAb
Human, Mouse, Rat

Mouse Monoclonal Antibody to Histone H1 (Mono Methyl Lys25)
HY-P80159

Histone H2A(acetyl K9) Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H2A (acetyl K9)
HY-P80160

Histone H2A(hydroxyl Y39) Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H2A(hydroxyl Y39)
HY-P80164

Histone H2B(acetyl K20) Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H2B(acetyl K20)
HY-P80171

Histone H3 (di methyl K9) Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H3 (di methyl K9)
HY-P80172

Histone H3 (mono methyl K18) Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H3 (mono methyl K18)
HY-P80173

Histone H3 (mono methyl K36)Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H3 (mono methyl K36)
HY-P80174

Histone H3 (mono methyl R2)Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H3 (mono methyl R2)
HY-P80176

Histone H3 (tri methyl K9) Mouse mAb
Human, Mouse, Rat

Mouse Monoclonal Antibody to Histone H3 (tri methyl K9)
HY-P80181

Histone H4 (tri methyl K20) Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H4 (tri methyl K20)
HY-P80165

Histone H2B(mono methyl R79) Rabbit mAb
Human, Mouse

Rabbit Monoclonal Antibody to Histone H2B(mono methyl R79)
HY-P80175

Histone H3 (mono+di+tri methyl K79) Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H3 (mono+di+tri methyl K79)
HY-P80699

HDAC2 (YP6076) Mouse mAb
HDAC2; histone deacetylase 2; HD2
Human, Mouse, Rat, Monkey

Mouse Monoclonal Antibody to HDAC2
HY-P80821

Phospho-Histone H2A.X (Ser139) Rabbit mAb
H2A.X; H2AFX; H2a/x; HIST5-2AX; histone H2A.X; gamma H2A.X
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H2A.X (Phospho Ser139)
HY-P80941

Phospho-Histone H2A.X (Ser139) (7G9) Mouse mAb
H2A.X; H2AFX; H2a/x; HIST5-2AX; histone H2A.X; gamma H2A.X
Human, Mouse

HY-P80700

HDAC4 (4A3) Mouse mAb EC 3.5.1.98; HA6116; HD 4; HD4; HDAC 4; HDAC A; HDAC4; HDAC4_HUMAN; HDACA; histone Deacetylase 4; histone Deacetylase A; KIAA0288.		Human, Mouse, Rat, Monkey
Mouse Monoclonal Antibody to HDAC4

HY-P80701

HDAC6 (YP6079) Mouse mAb
HDAC6; KIAA0901; JM21; histone deacetylase 6; HD6
Human, Rat

Mouse Monoclonal Antibody to HDAC6
HY-P80775

p300 Rabbit pAb
EP300; P300; histone acetyltransferase p300; p300 HAT; E1A-associated protein p300
Human, Mouse, Rat

Rabbit Polyclonal Antibody to KAT3B / p300
HY-P80463

Phospho-Histone H2A.X(S139) Rabbit mAb
Human, Mouse, Rat

Rabbit Monoclonal Antibody to Histone H2A.X(phospho S139)

HY-P80731

KDM1A (YP7017) Mouse mAb KDM1A; AOF2; KDM1; KIAA0601; LSD1; Lysine-specific histone demethylase 1A; BRAF35-HDAC complex protein BHC110; Flavin-containing amine oxidase domain-containing protein 2		Human, Mouse, Monkey
Mouse Monoclonal Antibody to KDM1/LSD1

HY-P80529

Acetyl-Histone H3 (Lys14) Rabbit mAb
H3K14ac; H3/j; H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3FJ; H3C10; H3C11; HIST1H3J
Human, Rat

Rabbit Monoclonal Antibody to Histone H3 (acetyl K14)
HY-P80530

Acetyl-Histone H3 (Lys27) Rabbit mAb
H3K27ac; H3/j; H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3FJ; H3C10; H3C11; HIST1H3J
Human

Rabbit Monoclonal Antibody to Histone H3 (acetyl K27)
HY-P80531

Acetyl-Histone H3 (Lys4) Rabbit mAb
H3K4ac; H3/j; H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3FJ; H3C10; H3C11; HIST1H3J
Human, Mouse

Rabbit Monoclonal Antibody to Histone H3 (Lys4)

histone

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products